NASDAQ:OYST Oyster Point Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oyster Point Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.54 +0.21 (+4.85%) (As of 07/1/2022 11:58 AM ET) Add Compare Share Today's Range$4.42▼$4.5450-Day Range$3.60▼$7.2652-Week Range$3.46▼$19.98Volume769 shsAverage Volume175,994 shsMarket Capitalization$121.08 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OYST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address OYST Stock Forecast (MarketRank)Overall MarketRank™1.86 out of 5 starsMedical Sector730th out of 1,429 stocksBiological Products, Except Diagnostic Industry117th out of 217 stocksAnalyst Opinion: 3.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 3.0 Analyst's Opinion Consensus RatingOyster Point Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Oyster Point Pharma has a forecasted upside of 329.9% from its current price of $4.42.Amount of Analyst CoverageOyster Point Pharma has received no research coverage in the past 90 days. Previous Next 3.2 Community Rank Outperform VotesOyster Point Pharma has received 29 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOyster Point Pharma has received 31 “underperform” votes. (Add your “underperform” vote.)Community SentimentOyster Point Pharma has received 51.67% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oyster Point Pharma and other stocks. Vote “Outperform” if you believe OYST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OYST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOyster Point Pharma does not currently pay a dividend.Dividend GrowthOyster Point Pharma does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oyster Point Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders17.90% of the stock of Oyster Point Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.32% of the stock of Oyster Point Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oyster Point Pharma are expected to grow in the coming year, from ($6.18) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oyster Point Pharma is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oyster Point Pharma is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOyster Point Pharma has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oyster Point Pharma (NASDAQ:OYST)Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Read More OYST Stock News HeadlinesJune 29, 2022 | finance.yahoo.comOyster Point Outlines Restructuring Plan With Savings Of Up To $48M In 2023June 29, 2022 | americanbankingnews.comOyster Point Pharma (NASDAQ:OYST) Stock Price Down 7.2%June 28, 2022 | seekingalpha.comOyster Point Pharma implementing cost-cutting plan with up to 50 jobs axedJune 28, 2022 | finance.yahoo.comOyster Point Pharma Announces Operating Expense Streamlining PlanJune 15, 2022 | finance.yahoo.comOyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®May 17, 2022 | nasdaq.comBitcoin Now Buys You the Greatest Amount of Oyster Point Pharma in the Past YearMay 8, 2022 | finance.yahoo.comEarnings Update: Oyster Point Pharma, Inc. (NASDAQ:OYST) Just Reported And Analysts Are Boosting Their EstimatesMay 8, 2022 | seekingalpha.comOyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call TranscriptMay 6, 2022 | finance.yahoo.comOyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Call TranscriptMay 5, 2022 | finance.yahoo.comOyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business HighlightsMay 4, 2022 | seekingalpha.comOyster Point Pharma Q1 2022 Earnings PreviewMay 3, 2022 | finance.yahoo.comOyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022April 27, 2022 | finance.yahoo.comOyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OYST CUSIPN/A CIK1720725 Webwww.oysterpointrx.com Phone609-382-9032FaxN/AEmployees303Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/01/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$23.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+318.5%Consensus RatingHold Rating Score (0-4)2 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100.66 million Net MarginsN/A Pretax Margin-475.87% Return on Equity-116.58% Return on Assets-68.61% Debt Debt-to-Equity Ratio1.62 Current Ratio7.27 Quick Ratio7.09 Sales & Book Value Annual Sales$24.54 million Price / Sales4.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book1.19Miscellaneous Outstanding Shares26,669,000Free Float21,895,000Market Cap$121.08 million OptionableNot Optionable Beta1.02 Oyster Point Pharma Frequently Asked Questions Should I buy or sell Oyster Point Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oyster Point Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Oyster Point Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OYST, but not buy additional shares or sell existing shares. View analyst ratings for Oyster Point Pharma or view top-rated stocks. What is Oyster Point Pharma's stock price forecast for 2022? 1 brokerages have issued 1 year target prices for Oyster Point Pharma's shares. Their OYST stock forecasts range from $15.00 to $23.00. On average, they anticipate Oyster Point Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 318.5% from the stock's current price. View analysts' price targets for Oyster Point Pharma or view top-rated stocks among Wall Street analysts. How has Oyster Point Pharma's stock performed in 2022? Oyster Point Pharma's stock was trading at $18.26 at the beginning of the year. Since then, OYST shares have decreased by 75.1% and is now trading at $4.54. View the best growth stocks for 2022 here. When is Oyster Point Pharma's next earnings date? Oyster Point Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Oyster Point Pharma. How were Oyster Point Pharma's earnings last quarter? Oyster Point Pharma, Inc. (NASDAQ:OYST) released its quarterly earnings results on Thursday, May, 5th. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.05. The company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.06 million. During the same period in the previous year, the business posted ($0.73) earnings per share. View Oyster Point Pharma's earnings history. Who are Oyster Point Pharma's key executives? Oyster Point Pharma's management team includes the following people: Dr. Jeffrey Nau MMS, Ph.D., Pres, CEO & Director (Age 47, Pay $962.85k)Mr. Daniel Lochner M.B.A., Chief Financial Officer (Age 39, Pay $642k)Mr. John Snisarenko M.B.A., Chief Commercial Officer (Age 59, Pay $634.95k)Mr. George Donato M.B.A., Sr. VP of CMC & OperationsDr. Eric Carlson Ph.D., Chief Scientific OfficerArty Ahmed, VP of Investor relationsMr. Barry Rosenfeld J.D., Sr. VP & Gen. CounselMs. Raegan A. McClain CCEP, J.D., L.L.M., Chief Compliance & Privacy OfficerMs. Karen Castillo-Paff, VP of Communications & PRMr. Dave Benadon, Chief HR Officer Who are some of Oyster Point Pharma's key competitors? Some companies that are related to Oyster Point Pharma include Immunovant (IMVT), Vaxart (VXRT), Monte Rosa Therapeutics (GLUE), Inhibrx (INBX), Aura Biosciences (AURA), Kodiak Sciences (KOD), ADMA Biologics (ADMA), Aerie Pharmaceuticals (AERI), C4 Therapeutics (CCCC), Adagio Therapeutics (ADGI), HilleVax (HLVX), Forma Therapeutics (FMTX), Humacyte (HUMA), MeiraGTx (MGTX) and Caribou Biosciences (CRBU). View all of OYST's competitors. What other stocks do shareholders of Oyster Point Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), (NGM), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT). When did Oyster Point Pharma IPO? (OYST) raised $85 million in an initial public offering on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO. What is Oyster Point Pharma's stock symbol? Oyster Point Pharma trades on the NASDAQ under the ticker symbol "OYST." How do I buy shares of Oyster Point Pharma? Shares of OYST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oyster Point Pharma's stock price today? One share of OYST stock can currently be purchased for approximately $4.54. How much money does Oyster Point Pharma make? Oyster Point Pharma (NASDAQ:OYST) has a market capitalization of $121.08 million and generates $24.54 million in revenue each year. The company earns $-100.66 million in net income (profit) each year or ($4.94) on an earnings per share basis. How many employees does Oyster Point Pharma have? Oyster Point Pharma employs 303 workers across the globe. How can I contact Oyster Point Pharma? Oyster Point Pharma's mailing address is 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540. The official website for Oyster Point Pharma is www.oysterpointrx.com. The company can be reached via phone at 609-382-9032 or via email at [email protected]. This page (NASDAQ:OYST) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
